<p>周五午盘交易时，天境生物（NASDAQ:IMAB）股价下跌了 3.8%。股价最低触及 1.23 美元，最后交易价为 1.26 美元。约有 150,879 股在交易中换手，较平均每日成交量 345,044 股下降了 56%。该股之前收盘价为 1.31 美元。</p>
<h2>华尔街分析师观点</h2>
<p>Needham &amp; Company LLC 单独重申了对天境生物股票的 “买入” 评级，并设定了 6.00 美元的目标价。这是在 4 月 12 日星期五的一份研究报告中提到的。</p>
<p><strong>阅读我们对天境生物的最新分析</strong></p>
<h2>天境生物股价下跌 3.8%</h2>
<p>该股的 50 天简单移动平均线为 1.63 美元，200 天简单移动平均线为 1.73 美元。</p>
<h2>对天境生物的对冲基金观点</h2>
<p>一家对冲基金最近在天境生物股票中新建了一个持股。根据该公司最近向美国证券交易委员会提交的文件，abrdn plc 在第四季度购入了天境生物 162,580 股，价值约 309,000 美元。截至最近一次提交给美国证券交易委员会的文件，abrdn plc 持有天境生物 0.20% 的股份。目前有 38.38% 的股份由机构投资者和对冲基金持有。</p>
<h2>关于天境生物</h2>
<p>天境生物是一家临床阶段的生物制药公司，致力于发现、开发和商业化生物制剂以治疗癌症和自身免疫性疾病。该公司正在开发 Felzartamab，一种用于治疗膜性肾病患者的 CD38 抗体，目前处于 1b/2a 期；Eftansomatropin alfa，一种长效生长激素，已完成 3 期临床试验，用于治疗儿童生长激素缺乏症；Efineptakin alfa，一种重组人 IL-7，用于治疗癌症相关淋巴细胞减少和癌症免疫治疗，目前处于 2 期；以及 Lemzoparlimab，一种 CD47 单克隆抗体，已完成 2 期临床试验。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们比天境生物更喜欢的股票</li>
<li>现在购买宝洁股票，趁它创下历史新高之前</li>
<li>你应该投资比特币吗？利弊分析</li>
<li>内部买盘解读：投资者需要了解的事项</li>
<li>亚马逊股票在人工智能泡沫破裂后有望强势反弹</li>
<li>如何选择评级最高的股票</li>
<li>壳牌股票：石油和天然气巨头致力于回购和股息</li>
</ul>
<p><em>此即时新闻警报由叙事科技和 MarketBeat 的财务数据生成，旨在为读者提供最快速和准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 能源行业每月股息的最大机会（来自 Investors Alley）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDI0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDI0"/></p>
<h2>现在是否值得投资 1,000 美元购买天境生物？</h2>
<p>在考虑天境生物之前，您应该听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票，然后再广泛市场注意到之前...而天境生物不在这份名单上。</p>
<p>尽管天境生物目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

天境生物

<p>天境生物（NASDAQ:IMAB）股价在周五的午间交易中下跌了 3.8%。该股票的 50 天简单移动平均线为$1.63，200 天简单移动平均线为$1.73。一家对冲基金最近新建了一笔在天境生物股票中的持股。天境生物是一家临床阶段生物制药公司，致力于开发生物制剂治疗癌症和自身免疫性疾病</p>

<p>I-Mab (NASDAQ:IMAB - Get Free Report) shares dropped 3.8% during mid-day trading on Friday . The stock traded as low as $1.23 and last traded at $1.26. Approximately 150,879 shares changed hands during trading, a decline of 56% from the average daily volume of 345,044 shares. The stock had previously closed at $1.31.</p>
<div class="lb-trans"><p>周五午盘交易时，天境生物（NASDAQ:IMAB）股价下跌了 3.8%。股价最低触及 1.23 美元，最后交易价为 1.26 美元。约有 150,879 股在交易中换手，较平均每日成交量 345,044 股下降了 56%。该股之前收盘价为 1.31 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Separately, Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $6.00 target price on shares of I-Mab in a research note on Friday, April 12th.</p>
<div class="lb-trans"><p>Needham &amp; Company LLC 单独重申了对天境生物股票的 “买入” 评级，并设定了 6.00 美元的目标价。这是在 4 月 12 日星期五的一份研究报告中提到的。</p>
</div><p><strong>Read Our Latest Analysis on I-Mab</strong></p>
<div class="lb-trans"><p><strong>阅读我们对天境生物的最新分析</strong></p>
</div><h2>I-Mab Stock Down 3.8 %</h2>
<div class="lb-trans"><h2>天境生物股价下跌 3.8%</h2>
</div><p>The stock has a 50 day simple moving average of $1.63 and a 200-day simple moving average of $1.73.</p>
<div class="lb-trans"><p>该股的 50 天简单移动平均线为 1.63 美元，200 天简单移动平均线为 1.73 美元。</p>
</div><h2>Hedge Funds Weigh In On I-Mab</h2>
<div class="lb-trans"><h2>对天境生物的对冲基金观点</h2>
</div><p>A hedge fund recently bought a new stake in I-Mab stock. abrdn plc bought a new position in I-Mab (NASDAQ:IMAB - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 162,580 shares of the company's stock, valued at approximately $309,000. abrdn plc owned 0.20% of I-Mab as of its most recent filing with the SEC. 38.38% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家对冲基金最近在天境生物股票中新建了一个持股。根据该公司最近向美国证券交易委员会提交的文件，abrdn plc 在第四季度购入了天境生物 162,580 股，价值约 309,000 美元。截至最近一次提交给美国证券交易委员会的文件，abrdn plc 持有天境生物 0.20% 的股份。目前有 38.38% 的股份由机构投资者和对冲基金持有。</p>
</div><h2>About I-Mab (Get Free Report)</h2>
<div class="lb-trans"><h2>关于天境生物</h2>
</div><p>I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial.</p>
<div class="lb-trans"><p>天境生物是一家临床阶段的生物制药公司，致力于发现、开发和商业化生物制剂以治疗癌症和自身免疫性疾病。该公司正在开发 Felzartamab，一种用于治疗膜性肾病患者的 CD38 抗体，目前处于 1b/2a 期；Eftansomatropin alfa，一种长效生长激素，已完成 3 期临床试验，用于治疗儿童生长激素缺乏症；Efineptakin alfa，一种重组人 IL-7，用于治疗癌症相关淋巴细胞减少和癌症免疫治疗，目前处于 2 期；以及 Lemzoparlimab，一种 CD47 单克隆抗体，已完成 2 期临床试验。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than I-Mab</li>
<li>Buy P&amp;G Now, Before It Sets A New All-Time High</li>
<li>Should You Invest in Bitcoin? Pros and Cons</li>
<li>Insider Buying Explained: What Investors Need to Know</li>
<li>Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts</li>
<li>How to Choose Top Rated Stocks</li>
<li>Shell Stock: Oil &amp; Gas Giant Committed to Buybacks and Dividends</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>五只我们比天境生物更喜欢的股票</li>
<li>现在购买宝洁股票，趁它创下历史新高之前</li>
<li>你应该投资比特币吗？利弊分析</li>
<li>内部买盘解读：投资者需要了解的事项</li>
<li>亚马逊股票在人工智能泡沫破裂后有望强势反弹</li>
<li>如何选择评级最高的股票</li>
<li>壳牌股票：石油和天然气巨头致力于回购和股息</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科技和 MarketBeat 的财务数据生成，旨在为读者提供最快速和准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Biggest opportunity for monthly dividends in the energy sector (From Investors Alley)(Ad)</p>
<div class="lb-trans"><p>→ 能源行业每月股息的最大机会（来自 Investors Alley）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDI0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9024&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in I-Mab right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1,000 美元购买天境生物？</h2>
</div><p>Before you consider I-Mab, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑天境生物之前，您应该听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and I-Mab wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票，然后再广泛市场注意到之前...而天境生物不在这份名单上。</p>
</div><p>While I-Mab currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管天境生物目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

天境生物（NASDAQ:IMAB）股价下跌 3.8%